An interventional study of ECG-Imaging in Ventricular Tachycardia, Ventricular Arrythmia and Ventricular Fibrillation, sponsored by Maastricht University Medical Center. Enrolling by invitation at 2 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-27.
Sponsored by Maastricht University Medical Center · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Tachycardia, Ventricular with a site in Netherlands — 10 open to participants now, 11 under way, none of them phase 3. Tachycardia, Ventricular · Netherlands.
Among the 34 studies in Tachycardia, Ventricular with a site in Netherlands, this one is the 10th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2020, is one of 13 with no phase, reaches primary completion later than 1 of the 10 other live ones, and was the 21st registered.
452 studies on the registry are indexed under Tachycardia, Ventricular; 121 are open to participants now.
Browse Tachycardia, Ventricular studies →10 of the 34 studies in Tachycardia, Ventricular with a site in Netherlands are open now. Recruiting first, the newest first:
Catharina Ziekenhuis Eindhoven · Sites in Netherlands
Ages 18+
AtaCor Medical, Inc. · Sites in Netherlands, United States
Ages 18+
Cardurion Pharmaceuticals, Inc. · Sites in Netherlands, United States, Canada and 3 more countries
Ages 18–99
Imricor Medical Systems · Sites in Netherlands, Germany
Ages 18+
Stereotaxis · Sites in Netherlands, Denmark, Lithuania and 1 more country
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 86 Tachycardia, Ventricular studies recruiting now, 67 (78%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 270 is above the median of 70 across 281 interventional studies indexed under Tachycardia, Ventricular.
Median enrollment 270 across the 19 interventional studies, 379 across the 15 observational. Of the 21 that completed or were terminated, 10 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 34 have an industry lead sponsor. The 10 most frequent:
Maastricht University Medical Center is the lead sponsor of 854 studies on the registry; 114 are open to participants now.
Maastricht University Medical Center has 3 studies filed under Tachycardia, Ventricular — fewer than ten, so there is no comparison to draw.
5 of the studies in Tachycardia, Ventricular with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04520347University of California, Los AngelesIVTCC 2.0: A Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry | 2026-12 |
| NCT06658899Cardurion Pharmaceuticals, Inc.A Phase 2 Study of CRD-4730 in CPVT | 2027-04 |
| NCT05543798Imricor Medical SystemsVT Ablation in the iCMR | 2027-07 |
| NCT05439031Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)StereoTactic Arrhythmia Radiotherapy in the NetherLands no. 2 | 2027-07 |
| NCT07324031AtaCor Medical, Inc.Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study | 2027-08-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 34 studies in Tachycardia, Ventricular with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the electrophysiological properties of the heart conduction system in patients with (increased risk of) ventricular tachyarrhythmias (VTA) and sudden cardiac arrest, and in a control cohort. The electrophysiological properties will be measured with the relatively new technique ECG-Imaging (ECGI). Moreover, clinical data of subjects will be gathered.
By combining the data from the data gathering and the results of ECGI, the investigators hope to increase mechanistic understanding of and risk stratification for VTAs. The investigators aim to be able to identify patients at risk of an arrhythmic event, and aim for better treatment strategies in the future.
ECGI combines electrical body-surface mapping with 256 electrodes placed on the thorax with a CT-scan obtaining the anatomy of the heart and torso, hereby able to reconstruct local electrograms, activation and recovery times. In recent research, ECGI provided numerous extra insights into normal cardiac electrophysiology, but also electrophysiological disorders and disease. The results strongly suggest that ECGI can play a pivotal role in further characterizing arrhythmia mechanisms, therefore could do so for VTAs, leading to diagnosis and treatment improvement. Moreover, ECGI seems to have the potential to detect arrhythmogenic substrate in individuals before their first event, offering the possibility to diagnose and treat patients before sudden cardiac arrest occurs.
In the BREACH-ECGI study:
ECGI will be used to noninvasively characterize the epicardial electrophysiological substrate and triggers of:
Moreover, clinical data of subjects will be gathered. These data will be analyzed to determine their prognostic value in terms of arrhythmia risk
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In order to be eligible to participate in this study, a subject must be ≥ 18 years old, have either a history of VTAs or be at risk of VTAs and have one of the following diagnoses:
Or: a subject must be ≥ 18 years old and have a structurally normal heart with a clinical indication for a cardiac CT.
Exclusion Criteria:
A potential subject who meets any of the following criteria will be excluded from participation in this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Control subjects receiving body-surface potential mapping (BSPM) and either a CT-scan or a CMR scan
Diagnostic Test: ECG-Imaging
Diseased subjects receiving body-surface potential mapping (BSPM) and either a CT-scan or a CMR scan. Outcome measures from these procedures will be compared to controls.
Diagnostic Test: ECG-Imaging
A body surface potential mapping and a cardiac + low dose CT-scan
ECG-Imaging outcome: epicardial potentials
reconstructed epicardial potentials, represented in mV over time(s).
Time frame: 3 years
ECG-Imaging outcome: activation and repolarization maps
Activation and repolarization maps. Acivation and repolarization times are determined from the epicardial potentials, expressed in ms. These are shown on a CT-derived or CMR-derived heart mesh. The entire activation and repolarization of the epicardium of the heart can be visualized this way.
Time frame: 3 years
(Possible) Prognostic risk factors for recurrent ventricular arrhythmias
Possible risk factors, found in the clinical data collection, expressed as odds/hazard ratio.
Time frame: 6 years
Recurrence of ventricular arrhythmias
Documentation over the period of follow-up, if subjects had a recurrence of ventricular arrythmia(s), presented as number of events over a time period.
Time frame: 6 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2020 (actual). Primary completion is estimated for Feb 2026, 68 months after the start.
Of 86 non-industry interventional studies with no phase under Tachycardia, Ventricular, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 70. This study's planned 68 months is above that.
Counting every sponsor, half of 126 studies reached it within 36 months; a quarter within 20 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Maastricht University Medical Center →